Skip to main contentSkip to main content
You have permission to edit this article.
Edit

Uptake Low for COVID-19 Vaccine Boosters in Immunocompromised Adults

  • Updated
  • 0
Uptake Low for COVID-19 Vaccine Boosters in Immunocompromised Adults

TUESDAY, Jan. 24, 2023 (HealthDay News) -- For immunocompromised adults, adherence to U.S. Centers for Disease Control and Prevention mRNA monovalent COVID-19 booster dose recommendations is low, according to a study published online Jan. 20 in JAMA Network Open.

Sara Y. Tartof, Ph.D., M.P.H., from Kaiser Permanente Southern California in Pasadena, and colleagues examined mRNA COVID-19 vaccine uptake and factors associated with uptake among immunocompromised adults from Dec. 14, 2020, through Aug. 6, 2022, in a cohort study. A total of 42,697 immunocompromised individuals met the eligibility criteria.

The researchers found that 78.0 percent of the immunocompromised individuals had received a third dose of mRNA COVID-19 vaccine, while only 41.0 percent had received a fourth dose, corresponding to a primary series and monovalent booster dose. Following the CDC recommendation to receive a second monovalent booster (fifth dose), only 0.9 percent had uptake. The likelihood of receiving at least four doses was increased for adults aged 65 years or older compared with those aged 18 to 44 or 45 to 64 years (hazard ratios, 3.95 and 2.52, respectively). The likelihood of receiving at least four doses was lower for Hispanic and non-Hispanic Black adults versus non-Hispanic White adults (hazard ratios, 0.77 and 0.82, respectively), for individuals with prior documented severe acute respiratory syndrome coronavirus 2 infection versus no infection (hazard ratio, 0.71), and for those receiving versus not receiving high-dose corticosteroids (hazard ratio, 0.88).

"Given the vulnerability of this population to develop severe COVID-19, a renewed focus on targeted and tailored efforts to ensure that immunocompromised individuals remain up to date with continuously evolving COVID-19 booster dose recommendations is warranted at this stage of the pandemic," the authors write.

Several authors disclosed financial ties to biopharmaceutical companies, including Pfizer, which funded the study.

Abstract/Full Text

0 Comments
0
0
0
0
0

Originally published on consumer.healthday.com, part of the TownNews Content Exchange.

* I understand and agree that registration on or use of this site constitutes agreement to its user agreement and privacy policy.

Related to this story

Most Popular

A bill under consideration in Washington state would make it the second state in the country to lower the legal limit for a driver’s blood alcohol content from 0.08% to 0.05%. Former state trooper and state Sen. John Lovick is sponsoring the bill. He said this week that hundreds of people were killed on roads in Washington last year in DUI-related incidents and that action should be taken to prevent more deaths. Josh McDonald, executive director of the Washington Wine Institute, spoke against the bill this week, saying it could turn modern consumption experiences into a “very serious concern.” Traffic deaths decreased in Utah after the state enacted a similar 0.05% law.

A phone’s camera lens can measure a heart rate. The microphone, kept by the bedside, can screen for sleep apnea. Even the speaker is being tapped, to monitor breathing. But using smartphones as diagnostic tools is a work in progress, experts say.

The South Dakota Senate has suspended a Republican state senator in a rare move that stripped her of legislative power while keeping the allegations against her a secret. Sen. Julie Frye-Mueller told reporters earlier Thursday that she was being punished following an exchange she had with a legislative aide about vaccinations. The Republican-controlled Senate voted to form a committee to investigate Frye-Mueller’s conduct and suspend her from voting or holding other rights of an elected official. Republican Sen. Michael Rohl, who initiated the motion to suspend Frye-Mueller, said in a statement that it was based on “serious allegations” and the need to ensure a safe working environment for employees. Frye-Mueller has opposed vaccination requirements in schools.

Scientists say delivering gene therapy directly to the brain holds great promise. The first brain-delivered gene therapy on the market was recently approved in Europe and the U.K. for a rare genetic disorder called AADC deficiency. It causes developmental delays and movement disorders in kids. New Jersey drugmaker PTC Therapeutics plans to seek approval for the treatment in the U.S. this year. Meanwhile, about 30 studies in the U.S. are testing gene therapy directly to the brain for other disorders, including Alzheimer’s and Parkinson’s. Challenges remain, especially with diseases caused by more than a single gene. But scientists say the evidence supporting this approach is mounting.

Imagine a time when your virus-blocking face covering is like an umbrella. Most days, it stays in your closet or is stowed somewhere in your car. But when a COVID-19 outbreak is in the forecast, you can put it to use. A group of would-be forecasters says it’s got the makings for such a system.

Listen now and subscribe: Apple Podcasts | Google Podcasts | Spotify | Stitcher | RSS Feed | Omny Studio

Get up-to-the-minute news sent straight to your device.

Topics

News Alerts

Breaking News